As a matter of patient convenience and accessibility, we are now providing clinical services remotely for patients in California who live beyond a 50 miles radius from either our West Los Angeles or Irvine Clinics.Learn More >>
OULU, Finland, Jan. 24 (UPI) — U.S. researchers looking at attention-deficit hyperactivity disorder in Finnish children confirm ADHD symptoms change with age. Read the article at UPI.
The study, published in the Journal of the American Academy of Child and Adolescent Psychiatry, confirms hyperactive and impulsive behaviors do decrease with age, while inattention increasingly becomes predominant.
Two-thirds of children with ADHD continue to exhibit significant levels of inattentiveness and impairment into adolescence, despite the differences between treatment approaches and cultures between the United States and Finland, the study said.
University of California, Los Angeles, researchers, led by Susan Smalley, looked at ADHD teens in Finland that were part of a long-term study begun prenatally in l986 by the Imperial College London and the University of Oulu, Finland.
The ADHD population in northern Finland exhibited two genes associated with ADHD known as DBH and DRD2. These genes affect the regulation of dopamine — a neurotransmitter involved in attention, motivation and emotion. Although the researchers say the genes likely account for very little of the genetic variation underlying ADHD, the findings further support the involvement of the dopamine pathway in the disorder.
If you or a family member need help, please fill out our confidential online form
Interview with Dr. David Velkoff
Interview with Dr. David Velkoff
Spanish News Feature
“David F. Velkoff, M.D., our Medical Director and co-founder, supervises all evaluation procedures and treatment programs. He is recognized as a physician pioneer in using biofeedback, qEEG brain mapping, neurofeedback, and neuromodulation in the treatment of ADHD, Autism Spectrum Disorders, and stress related illnesses including anxiety, depression, insomnia, and high blood pressure. Dr. David Velkoff earned his Master’s degree in Psychology from the California State University at Los Angeles in 1975, and his Doctor of Medicine degree from Emory University School of Medicine in Atlanta in 1976. This was followed by Dr. Velkoff completing his internship in Obstetrics and Gynecology with an elective in Neurology at the University of California Medical Center in Irvine. He then shifted his specialty to Neurophysical Medicine and received his initial training in biofeedback/neurofeedback in Neurophysical Medicine from the leading doctors in the world in biofeedback at the renown Menninger Clinic in Topeka, Kansas. In 1980, he co-founded the Drake Institute of Neurophysical Medicine. Seeking to better understand the link between illness and the mind, Dr. Velkoff served as the clinical director of an international research study on psychoneuroimmunology with the UCLA School of Medicine, Department of Microbiology and Immunology, and the Pasteur Institute in Paris. This was a follow-up study to an earlier clinical collaborative effort with UCLA School of Medicine demonstrating how the Drake Institute's stress treatment resulted in improved immune functioning of natural killer cell activity. Dr. Velkoff served as one of the founding associate editors of the scientific publication, Journal of Neurotherapy. He has been an invited guest lecturer at Los Angeles Children's Hospital, UCLA, Cedars Sinai Medical Center-Thalians Mental Health Center, St. John's Hospital in Santa Monica, California, and CHADD. He has been a medical consultant in Neurophysical Medicine to CNN, National Geographic Channel, Discovery Channel, Univision, and PBS.”